Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9% – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price dropped 2.9% on Tuesday . The stock traded as low as $13.61 and last traded at $13.72. Approximately 58,980 shares were traded during trading, a decline of 95% from the average daily volume of 1,196,164 shares. The stock had previously closed at $14.13.

Analysts Set New Price Targets

CAPR has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Oppenheimer restated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group increased their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Piper Sandler began coverage on Capricor Therapeutics in a report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Price Performance

The business has a 50-day moving average of $17.68 and a 200 day moving average of $10.46. The company has a market capitalization of $637.03 million, a PE ratio of -13.22 and a beta of 3.98.

Institutional Trading of Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its holdings in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Marshall Wace LLP bought a new position in Capricor Therapeutics during the second quarter valued at $426,000. Point72 Asset Management L.P. purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth $3,806,000. The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth about $161,000. Finally, BNP Paribas Financial Markets raised its position in shares of Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 15,872 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.